A detailed history of Callan Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 3,221 shares of BIIB stock, worth $630,124. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,221
Previous 3,041 5.92%
Holding current value
$630,124
Previous $655,000 13.89%
% of portfolio
0.06%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$190.52 - $236.72 $34,293 - $42,609
180 Added 5.92%
3,221 $746,000
Q1 2024

May 03, 2024

BUY
$212.02 - $267.71 $47,280 - $59,699
223 Added 7.91%
3,041 $655,000
Q4 2023

Feb 02, 2024

BUY
$222.59 - $267.94 $73,232 - $88,152
329 Added 13.22%
2,818 $729,000
Q3 2023

Nov 06, 2023

SELL
$253.3 - $285.89 $38,248 - $43,169
-151 Reduced 5.72%
2,489 $639,000
Q4 2022

Feb 13, 2023

BUY
$252.44 - $306.72 $666,441 - $809,740
2,640 New
2,640 $731,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28.2B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Callan Capital, LLC Portfolio

Follow Callan Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Capital, LLC with notifications on news.